BioSpace News Archive

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will host a live webcast on Wednesday, May 4th at 11:30 a.m. Eastern Time to discuss its first quarter financial results and report on pipeline and business progress.

Clover Biopharmaceuticals, Ltd. today announced additional data from SPECTRA, a global pivotal Phase 2/3 clinical trial, that shows SCB-2019 (CpG 1018/Alum) provides significant incremental protection against COVID-19.

Clinical benefit again observed for OTO-413 versus placebo for multiple efficacy endpoints based on responder analysis at both Days 57 and 85 Results support clinical activity and tolerability findings from previous Phase 1/2 trial Enrollment in higher dose cohorts is ongoing with results expected in second half of 2022 Otonomy expects to initiate full dose-ranging Phase 2 efficacy trial by the end of 2022 Management will review results during a conference call today at 8:30 a.m. E

Marinus Pharmaceuticals, Inc. today announced that it plans to release financial results for the first quarter ended March 31, 2022 after the market closes on May 12, 2022.

MiMedx Group, Inc. today announced that it will report operating and financial results for the first quarter ended March 31, 2022 after the market close on Tuesday, May 3, 2022.

Heat Biologics, Inc. today announced it has completed the acquisition of Elusys Therapeutics, Inc.

Ultragenyx Pharmaceutical Inc. today announced the first patient has been dosed in a clinical study for the treatment of Osteogenesis Imperfecta (OI) in patients ages 5 to <26 years of age.

Rockwell Medical, Inc. today announced that the company is scheduled to present at the Noblecon18 , Noble Capital Market’s 18th Annual Investor Conference in Hollywood, Florida, on Thursday, April 21st at 10:00 AM ET.

SCYNEXIS, Inc. announced the presentation of interim data from its ongoing Phase 3 FURI and CARES studies, as well as multiple posters regarding studies of ibrexafungerp at the 32nd European Congress of Clinical Microbiology and Infectious Diseases being held in Lisbon, Portugal, April 23-26, 2022.

Schrödinger will report its first quarter 2022 financial results on Wednesday, May 4, 2022, after the financial markets close.